Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials

ClinicalLIVEUpdated 18 Nov 2026

New Clinical Trials

Clinical trials companies registered in the last 30 days, worldwide, with the sponsor, phase and countries.

Sources: ClinicalTrials.gov · Rebuilt weekly · Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase.

Trials
777
in the 30 days to 2026-11-18
Added in 30 days
777
to 18 Nov 2026
Top country
United States
192 · 25% of the list
Phase covered
8
distinct values
Snapshot · 18 Nov 2026
Explore all 777

Signals

What the register says this week, and why it matters if you sell into it.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
  3. 174 of the listed studies are device, diagnostic or digital-health studies (no drug phase).
  4. A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

Export the full new clinical trials

777 rows as a .csv. Free. Every field, with its source link.

Country
Phase 1
Study type
208 / 777 trials
PostedSponsorStudyPhaseStatus
18 Nov 2026Beijing Baheal Wisart Medical Research Co., LtdChinaSafety, Tolerability, and Pharmacokinetic Study of Single and Multiple Ascending Dose of YY524051 Tablets in Healthy Adults.Phase 1Not Yet Recruiting18 Nov 2026Chengdu Zenitar Biomedical Technology Co., LtdAustraliaA Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular RiskPhase 1Not Yet Recruiting18 Nov 2026Cugene Inc.United StatesA Phase I Dose-Escalation Study of CUG279 in Participants With Select Advanced or Metastatic Solid TumorsPhase 1Recruiting18 Nov 2026Eli Lilly and CompanyChinaA Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy ParticipantsPhase 1Not Yet Recruiting18 Nov 2026Fujian Akeylink Biotechnology Co., Ltd.ChinaA Study on the Pharmacokinetics and Safety of GST-HG141 Tablets in Participants With Hepatic Impairment and Normal Liver FunctionPhase 1Recruiting18 Nov 2026Gan & Lee Pharmaceuticals.ChinaA Pharmacokinetics Study of GZR33 Injection at Different Injection SitesPhase 1Not Yet Recruiting18 Nov 2026Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsUnited StatesAleniglipron Renal Impairment StudyPhase 1Not Yet Recruiting18 Nov 2026Immorna Biotherapeutics, Inc.Phase 1 Trial to Assess Safety and Immunogenicity of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)Phase 1Not Yet Recruiting18 Nov 2026MultiValent Biotherapies, Inc.United StatesA Phase 1 Study of MVB-101 Administered Intraprostatically in Patients With Localized Prostate Cancer Who Are Scheduled for Radical ProstatectomyPhase 1Recruiting18 Nov 2026Novo Nordisk A/SUnited StatesExamination of How the Duration of Fasting and Temporary Stopping of Zenagamtide Dosing Affect the Amount of Food Left in the Stomach in Adults With Overweight or Obesity, With or Without Type 2 DiabetesPhase 1Not Yet Recruiting18 Nov 2026SanofiFirst-in-human Study of SAR448632 in Healthy Adult ParticipantsPhase 1Not Yet Recruiting18 Nov 2026Shanghai Henlius BiotechAustralia, ChinaA Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid TumorsPhase 1Not Yet Recruiting18 Nov 2026Trevi TherapeuticsUnited StatesA Study of the Potential Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine Extended-Release Tablets (NAL ER) in Healthy ParticipantsPhase 1Recruiting18 Nov 2026Xiamen Amoytop Biotech Co., Ltd.ChinaPhase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis BPhase 1Not Yet Recruiting17 Nov 2026Aerys BiosciencesAustraliaFirst-in-Human Study of ABS-169 in Healthy VolunteersPhase 1Not Yet Recruiting17 Nov 2026Aligos TherapeuticsUnited StatesSafety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)Phase 1Not Yet Recruiting17 Nov 2026Ashvattha Therapeutics, Inc.United StatesStudy Evaluating Safety & Tolerability of Migaldendranib in US Healthy VolunteersPhase 1Active Not Recruiting17 Nov 2026Beijing Xunsheng Biomedical Research Co., Ltd.ChinaAVL-102 for the Treatment of HPV 16/18/52/58-Related High-Grade LesionsPhase 1Recruiting17 Nov 2026CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.ChinaA Study of SYH2053 Injection in Participants With Hepatic Impairment Compared to Participants With Normal Hepatic FunctionPhase 1Recruiting17 Nov 2026Eli Lilly and CompanyUnited StatesA Study of LY3945262 in Healthy ParticipantsPhase 1Not Yet Recruiting17 Nov 2026GRIN Therapeutics, Inc.A Phase 1b Study of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder Caused by Non-Gain-of-Function VariantsPhase 1Not Yet Recruiting17 Nov 2026Innatus Therapeutics (Shanghai) Co., Ltd.ChinaA Phase I Study of INT-1868 Tablets in Healthy Adult Participants (INT-1868-I101)Phase 1Not Yet Recruiting17 Nov 2026Janssen Research & Development, LLCA Study of JNJ-99220732 in Participants With Advanced or Metastatic Solid TumorsPhase 1Not Yet Recruiting17 Nov 2026Novartis PharmaceuticalsA Safety and Tolerability Study of HJB647 in Adult Participants With Uncontrolled HypertensionPhase 1Not Yet Recruiting17 Nov 2026Novo Nordisk A/SUnited StatesA Research Study Investigating How a New Medicine NNC0721-5186 Works in Women Living With Overweight or ObesityPhase 1Not Yet Recruiting17 Nov 2026Reistone Biopharma Company LimitedChinaA Study of RSS0343 Tablets in Healthy Participants and in Participants With Mild or Moderate Renal ImpairmentPhase 1Not Yet Recruiting17 Nov 2026SystImmune Inc.United StatesA Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid TumorsPhase 1Recruiting16 Nov 2026AkesoChinaA Study of AK158D1 in Advanced Solid TumorsPhase 1Not Yet Recruiting16 Nov 2026Beijing Jiake Ruikang Pharmaceutical Technology Co., Ltd.ChinaSafety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of JAR-2203 in Healthy Participants With Elevated Plasma Lipoprotein(a)Phase 1Recruiting16 Nov 2026Boehringer IngelheimGermanyA Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or ObesityPhase 1Not Yet Recruiting16 Nov 2026Chendu DIAO Pharmaceutical Group CO., LTD.ChinaPharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Varying Degrees of Renal Impairment and Normal Renal FunctionPhase 1Recruiting16 Nov 2026Chengdu Suncadia Medicine Co., Ltd.ChinaA Study of HRS-8046 in Patients With Advanced Solid Tumors: Safety, Tolerability, and PharmacokineticsPhase 1Not Yet Recruiting16 Nov 2026CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.ChinaA Study of SYH2053 Injection in Participants With Renal Impairment Compared to Participants With Normal Renal FunctionPhase 1Recruiting16 Nov 2026Hanmi Pharmaceutical Company LimitedSouth KoreaA Study to Evaluate the Pharmacokinetics and Safety Between HIP2604 and RLD2606 in Healthy VolunteersPhase 1Not Yet Recruiting16 Nov 2026Merck Sharp & Dohme LLCA Study of V951A in Healthy Participants (V951A-001)Phase 1Not Yet Recruiting16 Nov 2026Shanghai Qilu Pharmaceutical Research and Development Center LTDA Phase I Study to Evaluate Single and Multiple Subcutaneous Administrations of QLS2406-1 Injection in Chinese Adult Participants With Overweight and Obesity.Phase 1Not Yet Recruiting16 Nov 2026Vaderis Therapeutics AGPharmacokinetics of Engasertib in Participants With and Without Hepatic ImpairmentPhase 1Not Yet Recruiting16 Nov 2026ViiV HealthcareAn Evaluation of the Potential for VH4011499 Drug-drug-interactionsPhase 1Not Yet Recruiting13 Nov 2026AbbVieUnited StatesA Study to Assess the Adverse Events and How Oral ABBV-1606 Moves Through the Body of Healthy Adult Participants.Phase 1Not Yet Recruiting13 Nov 2026Eli Lilly and CompanyUnited States, SingaporeA Study Assessing Eloralintide (LY3841136) in Healthy ParticipantsPhase 1Not Yet Recruiting13 Nov 2026Hangzhou Sciwind Biosciences Co., Ltd.ChinaA Phase I Study to Evaluate the Food Effect on Ecnoglutide TabletPhase 1Not Yet Recruiting13 Nov 2026Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.ChinaPhase I Study of HW281171 Tablets in Healthy ParticipantsPhase 1Not Yet Recruiting13 Nov 2026Korea United Pharm. Inc.South KoreaSafety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy AdultsPhase 1Not Yet Recruiting13 Nov 2026Nanjing Immunophage Biotech Co., LtdChinaStudy of IPG1094 Tablets in Chinese Healthy Adults and Obese AdultsPhase 1Not Yet Recruiting13 Nov 2026Priothera SASSingle and Multiple Ascending Dose Study of KRP-203 in Healthy Japanese AdultsPhase 1Completed13 Nov 2026Shanghai Henlius BiotechAustralia, ChinaA Phase I Study of HLX109 in Healthy ParticipantsPhase 1Not Yet Recruiting13 Nov 2026Suzhou Siran Biotechnology Co.,Ltd.ChinaSA030 Injection in Healthy ParticipantsPhase 1Not Yet Recruiting13 Nov 2026UCB Biopharma SRLA Study to Evaluate the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic Lupus Erythematosus Who Are Administered Dapirolizumab PegolPhase 1Not Yet Recruiting13 Nov 2026ViiV HealthcareMass Balance and Absolute Bioavailability of [14C]-VH4011499Phase 1Not Yet Recruiting13 Nov 2026Zhuhai Hengqin ImStem Biotechnology Co., Ltd.ChinaA Study of IMS001 in Patients With Multiple SclerosisPhase 1Recruiting

// How AOS uses this

Every row here is a potential account. AOS finds the ones that need what you sell, maps the decision makers and prepares the outreach for your approval.